Welcome to LookChem.com Sign In|Join Free
  • or
(4-OXO-4H-QUINAZOLIN-3-YL)-ACETIC ACID METHYL ESTER is a chemical compound with the molecular formula C11H10N2O3. It is an ester derivative of acetic acid and contains a quinazolin-4-one moiety. (4-OXO-4H-QUINAZOLIN-3-YL)-ACETIC ACID METHYL ESTER may have potential applications in the pharmaceutical industry due to its quinazolinone core, which has been reported to exhibit various biological activities such as anticancer, anti-inflammatory, and antifungal properties. The ester functional group in (4-OXO-4H-QUINAZOLIN-3-YL)-ACETIC ACID METHYL ESTER suggests that it may have some degree of lipophilicity, which could affect its solubility and distribution in biological systems. Further research and testing are required to fully understand the properties and potential uses of (4-OXO-4H-QUINAZOLIN-3-YL)-ACETIC ACID METHYL ESTER.
Used in Pharmaceutical Industry:
(4-OXO-4H-QUINAZOLIN-3-YL)-ACETIC ACID METHYL ESTER is used as a potential pharmaceutical agent for its reported biological activities. The quinazolinone core of (4-OXO-4H-QUINAZOLIN-3-YL)-ACETIC ACID METHYL ESTER has been associated with anticancer, anti-inflammatory, and antifungal properties, making it a candidate for the development of new drugs targeting these therapeutic areas.
Used in Drug Development:
(4-OXO-4H-QUINAZOLIN-3-YL)-ACETIC ACID METHYL ESTER is used as a starting material or intermediate in the synthesis of more complex drug molecules. Its quinazolinone core and ester functional group can be further modified or combined with other chemical entities to create new compounds with improved pharmacological properties.
Used in Research and Testing:
(4-OXO-4H-QUINAZOLIN-3-YL)-ACETIC ACID METHYL ESTER is used as a research compound to study its biological activities and potential therapeutic applications. Further research is required to understand its properties, mechanism of action, and safety profile, which can inform the development of new drugs based on (4-OXO-4H-QUINAZOLIN-3-YL)-ACETIC ACID METHYL ESTER.
Used in Medicinal Chemistry:
(4-OXO-4H-QUINAZOLIN-3-YL)-ACETIC ACID METHYL ESTER is used as a scaffold or template in medicinal chemistry for the design and optimization of new drug candidates. Its quinazolinone core and ester functional group can be modified to explore structure-activity relationships and identify compounds with improved potency, selectivity, and pharmacokinetic properties.

54368-19-3

Post Buying Request

54368-19-3 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

54368-19-3 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 54368-19-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,4,3,6 and 8 respectively; the second part has 2 digits, 1 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 54368-19:
(7*5)+(6*4)+(5*3)+(4*6)+(3*8)+(2*1)+(1*9)=133
133 % 10 = 3
So 54368-19-3 is a valid CAS Registry Number.
InChI:InChI=1/C11H10N2O3/c1-16-10(14)6-13-7-12-9-5-3-2-4-8(9)11(13)15/h2-5,7H,6H2,1H3

54368-19-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name methyl 2-(4-oxoquinazolin-3-yl)acetate

1.2 Other means of identification

Product number -
Other names methyl(4-oxoquinazolin-3(4h)-yl)acetate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:54368-19-3 SDS

54368-19-3Relevant academic research and scientific papers

Optimization of a Novel Quinazolinone-Based Series of Transient Receptor Potential A1 (TRPA1) Antagonists Demonstrating Potent in Vivo Activity

Schenkel, Laurie B.,Olivieri, Philip R.,Boezio, Alessandro A.,Deak, Holly L.,Emkey, Renee,Graceffa, Russell F.,Gunaydin, Hakan,Guzman-Perez, Angel,Lee, Josie H.,Teffera, Yohannes,Wang, Weiya,Youngblood, Beth D.,Yu, Violeta L.,Zhang, Maosheng,Gavva, Narender R.,Lehto, Sonya G.,Geuns-Meyer, Stephanie

, p. 2794 - 2809 (2016/04/10)

There has been significant interest in developing a transient receptor potential A1 (TRPA1) antagonist for the treatment of pain due to a wealth of data implicating its role in pain pathways. Despite this, identification of a potent small molecule tool possessing pharmacokinetic properties allowing for robust in vivo target coverage has been challenging. Here we describe the optimization of a potent, selective series of quinazolinone-based TRPA1 antagonists. High-throughput screening identified 4, which possessed promising potency and selectivity. A strategy focused on optimizing potency while increasing polarity in order to improve intrinisic clearance culminated with the discovery of purinone 27 (AM-0902), which is a potent, selective antagonist of TRPA1 with pharmacokinetic properties allowing for >30-fold coverage of the rat TRPA1 IC50 in vivo. Compound 27 demonstrated dose-dependent inhibition of AITC-induced flinching in rats, validating its utility as a tool for interrogating the role of TRPA1 in in vivo pain models.

Development of 2-(4-oxoquinazolin-3(4 H)-yl)acetamide derivatives as novel enoyl-acyl carrier protein reductase (InhA) inhibitors for the treatment of tuberculosis

Pedgaonkar, Ganesh S.,Sridevi, Jonnalagadda Padma,Jeankumar, Variam Ullas,Saxena, Shalini,Devi, Parthiban Brindha,Renuka, Janupally,Yogeeswari, Perumal,Sriram, Dharmarajan

, p. 613 - 627 (2015/01/09)

InhA, the enoyl acyl carrier protein reductase of Mycobacterium tuberculosis (MTB) is an attractive target for developing novel anti-tubercular agents. Twenty eight 2-(4-oxoquinazolin-3(4H)-yl)acetamide derivatives were synthesized and evaluated for their in vitro MTB InhA inhibition. Compounds were further evaluated for their in vitro activity against drug sensitive and resistant MTB strains and cytotoxicity against RAW 264.7 cell line. Compounds were docked at the active site of InhA to understand their binding mode and differential scanning fluorimetry was performed to ascertain their protein interaction and stability.

Mukaiyama's reagent promoted C-N bond formation: a new method to synthesize 3-alkylquinazolin-4-ones

Punthasee, Puminun,Vanitcha, Avassaya,Wacharasindhu, Sumrit

supporting information; experimental part, p. 1713 - 1716 (2010/05/03)

A new approach to synthesize 3-alkylquinazolin-4-ones is developed. Treatment of quinazolin-4-ones with Mukaiyama's reagent, a base and a primary amine nucleophile results in the formation of 3-alkylquinazolin-4-ones in moderate to good yields under mild conditions. Using this methodology, a one-step synthesis of the natural alkaloid, echinozolinone, is accomplished.

Synthesis of 2,3-dihydro-4(1H)-quinazolinones

Escalante, Jaime,Flores, Patricia,Priego, Jaime M.

, p. 2019 - 2032 (2007/10/03)

An improved procedure for the synthesis of 2-substituted 2,3-dihydro-4(1H)-quinazolinones through diastereomer separation of the corresponding quinazolinones derivatives is presented. The determination of their absolute configurations was obtained by X-Ra

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 54368-19-3